A Phase II Trial of Suberoylanilide Hydroxamic Acid for Recurrent or Primary Refractory Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2013
At a glance
- Drugs Vorinostat (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 Jun 2011 Planned end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 08 Aug 2007 Status change from suspended to in progress.
- 19 Jan 2007 Status change from Recruiting to Suspended